Allen B. King

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Alan J. Garber, Allen B. King, Stefano Del Prato et al. · The Lancet · 2012 · 323 citations

Diabetes Management, Insulin Degludec, Diabetes +7

A Bolus Calculator Is an Effective Means of Controlling Postprandial Glycemia in Patients on Insulin Pump Therapy

Todd M. Gross, David Kayne, Allen B. King et al. · Diabetes Technology & Therapeutics · 2003 · 143 citations

Metabolic Syndrome, Diabetes Management, Body Composition +15

Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes

Irl B. Hirsch, Bruce W. Bode, J.P. Courrèges et al. · Diabetes Care · 2012 · 75 citations · Full text

Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal‐only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14‐week follow‐up data from PREDICTIVE™

Anne Dornhorst, H.‐J. Lüddeke, Christoph Koenen et al. · Diabetes Obesity and Metabolism · 2007 · 56 citations

Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs

Allen B. King, Poon · Drug Healthcare and Patient Safety · 2010 · 55 citations · Full text